Alamar Biosciences launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alamar-NULISAqpcr

More Like This

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

PR Newswire associated0

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

PR Newswire associated0

Alamar Biosciences Launches Certified Service Provider Program to Expand Access to NULISA technology for Academic and Biopharmaceutical Researchers

PR Newswire associated0

Alamar Biosciences Unveils NULISAseq Inflammation Panel AQ

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Alamar Biosciences logo (Graphic: Business Wire)

ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

GlobeNewswire associated0

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

PR Newswire associated0

Alamar Biosciences Achieves ISO 13485 Certification, Demonstrating its Commitment to Quality and Safety